12:00 AM
 | 
Apr 24, 2000
 |  BC Week In Review  |  Company News  |  Deals

BTG, CeNeS deal

CEN subsidiary CeNeS Drug Discovery Ltd. extended its license to BTG's hydrogel sustained release delivery technology. CEN has global rights to apply the technology to...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >